Author's response to reviews

Title: Pathological complete response in advanced gastric stromal tumour after imatinib mesylate therapy: A case report

Authors:

El Mesbahi Omar (elmesbahiomar@yahoo.fr)
Brahmi Sami aziz (brahmi2007@gmail.com)
Akasbi Yousra (you.yous@hotmail.fr)
El Mrabet fatema zahra (fazoumed@hotmail.com)
Touyar Anass (touyar.anass79@hotmail.com)
Oussaden Abdelmalek (aousadden@yahoo.fr)
Znati Kaoutar (kaoutarznati@yahoo.fr)
Maazaz (khalidmaazaz@caramail.com)
Amarti Affaf (amartiafaf@yahoo.fr)
Tizniti Siham (sihamtizniti@yahoo.fr)
Ait Taleb Khaled (khaittaleb@gmail.com)
Ibrahim Adil (gastrochufes@hotmail.com)

Version: 2 Date: 20 October 2010

Author's response to reviews: see over
Response to reviewers:

Reviewer 1:

I would like to thank you for the interest you did to the manuscript: Pathological complete response in advanced gastric stromal tumour after imatinib mesylate therapy: A case report

I have rewritten the manuscript according to your comments and adding some language corrections

Comment n°1:
The results of PET scan: the patient did not underwent a $^{18}$F-FDG PET scan because it is not available in Morocco

Comment n°2:
The molecular biology of the GIST: The molecular biology was not done

Comment n°3:
The reference of mandala's clinical case reporting a pathologic complete response is added

Comment n°4:
Mutational analysis may help to exclude less sensitive mutational status (e.g. PDGFRA D842V mutations) from therapy with imatinib or to tailor design. So that it may help to make a decision: surgery or neoadjuvant therapy for resectable disease.

Comment n°5:
The benefit of adjuvant imatinib therapy after neoadjuvant therapy is still in exploration. To our knowledge, no studies have reported evaluating this strategy.

Comment n°6:

English correction is done.
Reviewer 2:

I would like to thank you for the interest you did to the manuscript: **Pathological complete response in advanced gastric stromal tumour after imatinib mesylate therapy: A case report**

I have rewritten the manuscript according to your comments and adding some language corrections:

**Major comments:**

Page 5, line 7:

If R0 surgery is not feasible, or it could be achieved through less mutilating surgery in the case of cytoreduction, imatinib pretreatment is recommended (ESMO 2010).

The molecular biology of the GIST: The molecular biology was not done. It will be done later in our institution molecular laboratory.

**Minor comments:**

We have corrected orthography missing

English correction is done